Cilcare is a French-US biopharmaceutical company pioneering auditory science, developing innovative drugs and diagnostics to prevent and treat hearing disorders. The company addresses a major unmet medical need worldwide: hearing loss, which is expected to affect nearly 2.5 billion people by 2050. Growing evidence identifies hearing loss as the leading modifiable risk factor for dementia. Through its integrated platform spanning therapeutic development, translational research, and AI-driven auditory analytics, Cilcare is committed to making hearing a global health priority and advancing precision medicine for patients worldwide.

Cilcare’s lead drug candidate, CIL001, targets cochlear synaptopathy, an early stage of hearing loss affecting an estimated 15% of the global population. It is characterized by difficulty understanding speech in noisy environments. This condition, which can be worsened by noise exposure, Alzheimer’s and Parkinson’s disease, may progress to more severe hearing loss if left untreated.

Founded in 2014 by three visionary women entrepreneurs, Cilcare is headquartered in France, with laboratories in Montpellier and Boston, and offices in Paris and Tokyo. The company employs a team of 50 international collaborators, supported by a scientific advisory board and surrounded by the most renowned experts (KOLs) in auditory science. With a strong track record of strategic partnerships with major players worldwide, Cilcare has established itself as a global leader in auditory science.